CORTEF (hydrocortisone cypionate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, temporal arteritis, polymyositis and 14 more indications. First approved in 1955.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
CORTEF (hydrocortisone cypionate) is an oral glucocorticoid suspension approved in 1955 for replacement therapy in adrenocortical deficiency and anti-inflammatory treatment across multiple organ systems. It works by modifying immune response and producing profound metabolic effects through glucocorticoid receptor activation. The drug treats conditions ranging from autoimmune diseases (SLE, rheumatoid arthritis) to allergic reactions and hematologic malignancies.
Product approaching loss of exclusivity with modest Part D utilization (2,769 claims, $683K spending in 2023); brand team will shift focus toward generics mitigation and niche positioning strategies.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Worked on CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCORTEF offers limited career growth opportunities due to LOE-approaching lifecycle status and minimal linked job postings (0 identified). Roles in this portfolio typically focus on legacy product defense, generic mitigation, and market access optimization rather than innovation or expansion.